Receptos Inc (NASDAQ:RCPT)

126.64
Delayed Data
As of Feb 27
 +0.13 / +0.10%
Today’s Change
24.53
Today|||52-Week Range
139.40
+3.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$4.0B

Company Description

Receptos, Inc. is a biopharmaceutical company. It discovers, develops and commercializes innovative therapeutics for immune disorders. The company clinical pipeline includes RPC1063 and RPC4046. The RPC1063 is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The RPC4046 developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. Receptos was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA.

Contact Information

Receptos, Inc.
10835 Road to the Cure
San Diego California 92121
P:(858) 652-5700
Investor Relations:

Employees

Shareholders

Mutual fund holders52.65%
Other institutional43.92%
Individual stakeholders22.43%

Top Executives

Faheem HasnainPresident, Chief Executive Officer & Director
Graham K. CooperCFO, CAO, Head-Investor & Media Relations
Robert J. PeachChief Scientific Officer
Marcus F. BoehmChief Technology Officer
Sheila GujrathiChief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account